Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) FCF Margin: 2023-2025

Historic FCF Margin for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -9,428.45%.

  • NewAmsterdam Pharma Co N.V's FCF Margin fell 938524.00% to -9,428.45% in Q3 2025 from the same period last year, while for Sep 2025 it was -410.12%, marking a year-over-year increase of 5076.00%. This contributed to the annual value of -349.49% for FY2024, which is 65294.00% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its FCF Margin stood at -9,428.45% for Q3 2025, which was down 4,680.52% from -197.23% recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year FCF Margin high stood at -43.20% for Q3 2024, and its period low was -9,428.45% during Q3 2025.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's FCF Margin averaged around -2,298.47%, with its median value being -1,597.59% (2023).
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 382,569bps in 2024, then tumbled by 938,524bps in 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's FCF Margin (Quarterly) stood at -4,119.18% in 2023, then soared by 382,569bps to -293.49% in 2024, then tumbled by 938,524bps to -9,428.45% in 2025.
  • Its FCF Margin was -9,428.45% in Q3 2025, compared to -197.23% in Q2 2025 and -1,225.12% in Q1 2025.